A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).

Trial Details

NCT ID
NCT06685796
Phase
PHASE2
Sponsor
BeBetter Med Inc
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • BEBT-209 capsules
  • Carboplatin injection
  • Gemcitabine hydrochloride for injection
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Age: ≥18 years old, female;
  • The subject has fully understood and is willing to sign the Informed Consent Form (ICF);
  • Confirmed diagnosis of HR-negative, HER2-negative locally recurrent or metastatic breast cancer by pathological biopsy;
  • Estrogen and progesterone receptor immunohistochemical assessment of tumor tissue is negative (defined as \<1% nuclear staining), and HER2 is negat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →